PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund modestly underperformed the S&P 1500 Health Care Index in the quarter which declined 1.1%. Security selection within pharmaceuticals, MedTech, and health care provides & services contributed the most value during the quarter, […]
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.